CRBP Key Statistics, Chart & Performance
The current stock price of CRBP is 10.66 USD. In the past month the price decreased by -16.42%. In the past year, price decreased by -32.63%.
CRBP Latest News, Press Relases and Analysis
CRBP Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.15 | 403.40B | ||
| AMGN | AMGEN INC | 15.71 | 184.99B | ||
| GILD | GILEAD SCIENCES INC | 15.21 | 154.54B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.37 | 116.13B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.32 | 77.19B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 932.73 | 62.84B | ||
| INSM | INSMED INC | N/A | 44.01B | ||
| NTRA | NATERA INC | N/A | 32.62B | ||
| BIIB | BIOGEN INC | 10.85 | 26.65B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.15 | 20.62B | ||
| INCY | INCYTE CORP | 15.78 | 19.89B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.24B |
Related stock screener links
About CRBP
Company Profile
Corbus Pharmaceuticals Holdings, Inc. is an oncology company, which engages in research, development, and commercializing therapeutics for cancer and obesity. The company is headquartered in Norwood, Massachusetts and currently employs 28 full-time employees. The company went IPO on 2014-10-24. The firm has a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The Company’s oncology pipeline comprises two experimental drugs targeting solid tumors: CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, and CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFB expressed on cancer cells. CRB-701 is a monoclonal antibody attached to a monomethyl auristatin E (MMAE) cytotoxic payload using a proprietary linker technology. The pipeline also includes CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. CB1 inverse agonism is a clinically validated mechanism to induce weight loss.
Company Info
CORBUS PHARMACEUTICALS HOLDI
500 River Ridge Drive
Norwood MASSACHUSETTS 02062 US
CEO: Yuval Cohen
Employees: 28
Phone: 16179630103
CORBUS PHARMACEUTICALS HOLDI / CRBP FAQ
What does CORBUS PHARMACEUTICALS HOLDI do?
Corbus Pharmaceuticals Holdings, Inc. is an oncology company, which engages in research, development, and commercializing therapeutics for cancer and obesity. The company is headquartered in Norwood, Massachusetts and currently employs 28 full-time employees. The company went IPO on 2014-10-24. The firm has a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The Company’s oncology pipeline comprises two experimental drugs targeting solid tumors: CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, and CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFB expressed on cancer cells. CRB-701 is a monoclonal antibody attached to a monomethyl auristatin E (MMAE) cytotoxic payload using a proprietary linker technology. The pipeline also includes CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. CB1 inverse agonism is a clinically validated mechanism to induce weight loss.
What is the current price of CRBP stock?
The current stock price of CRBP is 10.66 USD. The price increased by 3.7% in the last trading session.
What is the dividend status of CORBUS PHARMACEUTICALS HOLDI?
CRBP does not pay a dividend.
What is the ChartMill technical and fundamental rating of CRBP stock?
CRBP has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the ownership structure of CORBUS PHARMACEUTICALS HOLDI (CRBP)?
You can find the ownership structure of CORBUS PHARMACEUTICALS HOLDI (CRBP) on the Ownership tab.
What is the Short Interest ratio of CORBUS PHARMACEUTICALS HOLDI (CRBP) stock?
The outstanding short interest for CORBUS PHARMACEUTICALS HOLDI (CRBP) is 5.91% of its float.
CRBP Technical Analysis
CRBP Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to CRBP. No worries on liquidiy or solvency for CRBP as it has an excellent financial health rating, but there are worries on the profitability.
CRBP Financial Highlights
Over the last trailing twelve months CRBP reported a non-GAAP Earnings per Share(EPS) of -5.51. The EPS decreased by -17.48% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -46.33% | ||
| ROE | -52.21% | ||
| Debt/Equity | 0 |
CRBP Forecast & Estimates
16 analysts have analysed CRBP and the average price target is 42.39 USD. This implies a price increase of 297.62% is expected in the next year compared to the current price of 10.66.